Charles IV - Psychemedics Ex VP
| PMD Stock | USD 2.34 0.01 0.43% |
Insider
Charles IV is Ex VP of Psychemedics
| Age | 58 |
| Address | 5220 Spring Valley Road, Dallas, TX, United States, 75254 |
| Phone | 800 527 7424 |
| Web | https://www.psychemedics.com |
Psychemedics Management Efficiency
The company has Return on Asset of (0.1624) % which means that on every $100 spent on assets, it lost $0.1624. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6133) %, meaning that it generated no profit with money invested by stockholders. Psychemedics' management efficiency ratios could be used to measure how well Psychemedics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.32. The current year's Return On Capital Employed is expected to grow to -0.36. At present, Psychemedics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 663.6 K, whereas Other Assets are forecasted to decline to about 1.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Zhihong Zhang | Burning Rock Biotech | 48 | |
| Andrew Macan | Neuronetics | 51 | |
| Robert Hauzie | Sotera Health Co | N/A | |
| MD FACR | Exagen Inc | N/A | |
| Alexander Dimitrief | Sotera Health Co | 65 | |
| Robert Harrison | Sera Prognostics | 58 | |
| Michael MD | Sera Prognostics | N/A | |
| MBA MBA | Sera Prognostics | 70 | |
| Kristin Gibbs | Sotera Health Co | N/A | |
| Sean MD | Sera Prognostics | N/A | |
| John Boniface | Sera Prognostics | 62 | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| Kara Thornton | Neuronetics | N/A | |
| Michael Biehl | Sotera Health Co | 68 | |
| Claire Sears | Neuronetics | N/A | |
| Paul Kearney | Sera Prognostics | 56 | |
| John Abbott | Castle Biosciences | N/A | |
| Zvi David | DarioHealth Corp | 63 | |
| Richard Anderson | DarioHealth Corp | 55 | |
| Ryan Douglas | Exagen Inc | N/A | |
| Stephen MS | Neuronetics | 60 | |
Management Performance
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.16 |
Psychemedics Leadership Team
Elected by the shareholders, the Psychemedics' board of directors comprises two types of representatives: Psychemedics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Psychemedics. The board's role is to monitor Psychemedics' management team and ensure that shareholders' interests are well served. Psychemedics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Psychemedics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Weisenhoff, Principal Manager | ||
| Raymond Kubacki, Chairman, CEO and Pres | ||
| Charles IV, Ex VP | ||
| Shannon Shoemaker, Chief Officer | ||
| Michael Schaffer, VP of Laboratory Operations | ||
| Werner Baumgartner, Founder | ||
| Annette Baumgartner, Founder | ||
| Sarah Ashby, VP Counsel | ||
| Patrick Kinney, Secretary | ||
| Brian Hullinger, CEO President | ||
| Daniella Mehalik, Vice Finance |
Psychemedics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Psychemedics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 13.97 M | ||||
| Shares Outstanding | 5.89 M | ||||
| Shares Owned By Insiders | 23.14 % | ||||
| Shares Owned By Institutions | 20.22 % | ||||
| Number Of Shares Shorted | 39.88 K | ||||
| Price To Earning | 92.08 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Psychemedics is a strong investment it is important to analyze Psychemedics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Psychemedics' future performance. For an informed investment choice regarding Psychemedics Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Earnings Share (0.51) | Revenue Per Share 3.586 | Quarterly Revenue Growth (0.15) | Return On Assets (0.16) |
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psychemedics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.